SomaLogic (NASDAQ:SLGC – Get Rating) and OmniAb (NASDAQ:OABI – Get Rating) are both small-cap business services companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.

Analyst Recommendations

This is a summary of recent ratings and price targets for SomaLogic and OmniAb, as provided by MarketBeat.

SomaLogic currently has a consensus price target of $11.00, indicating a potential upside of 340.00%. OmniAb has a consensus price target of $10.25, indicating a potential upside of 164.18%. Given SomaLogic's higher possible upside, equities research analysts plainly believe SomaLogic is more favorable than OmniAb.

Insider and Institutional Ownership

Earnings & Valuation

This table compares SomaLogic and OmniAb's gross revenue, earnings per share and valuation.

OmniAb has lower revenue, but higher earnings than SomaLogic.

Risk & Volatility

SomaLogic has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, OmniAb has a beta of -1.18, indicating that its share price is 218% less volatile than the S&P 500.

Profitability

This table compares SomaLogic and OmniAb's net margins, return on equity and return on assets.

About SomaLogic

(Get Rating)

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.

About OmniAb

(Get Rating)

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

Receive News & Ratings for SomaLogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SomaLogic and related companies with MarketBeat.com's FREE daily email newsletter.